

# Financial Tear Sheet

## Corporate Profile

We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.

## Stock Performance

### XENE (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$3.20</b>
<b>Change (%)</b>	▼ 0.05 (1.54%)
<b>Volume</b>	15,545
<b>52 Week Low</b>	\$2.25
<b>Market Cap</b>	\$58,494,865
<b>Rolling EPS</b>	-1.67
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	17,998,420

Data as of 10/23/17 3:23 p.m. ET



## Recent Press Releases & Upcoming Events

**October 17, 2017** - Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial

There are currently no events scheduled.

**August 3, 2017** - Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update

**July 27, 2017** - Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update

## SEC Filings

Filing Date	Form
09/25/17	4
09/18/17	CT ORDER
09/05/17	CT ORDER
08/21/17	4

## Corporate Governance

Simon Pimstone, MBChB, Ph.D., FRCPC

Ian Mortimer, MBA, CPA, CMA

Y. Paul Goldberg, MBChB, Ph.D., FRCPC

Robin Sherrington, Ph.D.

Charles Cohen, PhD

James Empfield, Ph.D.

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources